Vascular Medicine and Investigation Department, INSERM CIC-1414, University of Rennes 2, M2S - EA 7470, F-35000 Rennes, France; Pôle imagerie médicale et explorations fonctionnelles, Hôpital Pontchaillou, 2 rue Henri Le Guilloux, Rennes F-35033, France.
Division of Angiology, Department of Internal Medicine, Medical University Graz, Auenbruggerplatz 27, 8036 Graz, Austria.
Diabetes Res Clin Pract. 2022 Feb;184:109214. doi: 10.1016/j.diabres.2022.109214. Epub 2022 Jan 24.
This survey aimed to evaluate the current management and screening of coronary artery disease and peripheral artery disease in people with type 2 diabetes mellitus (T2DM) in Europe, utilizing the 2013 ESC/EASD (European Society of Cardiology/European Association for the Study of Diabetes) guidelines as a benchmark.
The PADDIA/CADDIA survey is a European medical research collaboration targeting cardiologists, vascular physicians, diabetologists and general practitioners from Austria, Belgium, France, Germany, Italy, Netherlands and United Kingdom.
The questionnaire was completed by sixty-three physicians, of whom 75% declared assessing the cardiovascular risk of people with T2DM mostly without using a risk score (59%). More than 90% of the panel, check HbA1c, blood pressure and low-density lipoprotein cholesterol targets in their patients with T2DM and coronary or peripheral artery disease. For 94% the presence of T2DM influence their patients' management, by optimizing blood glucose, blood pressure and low-density lipoprotein cholesterol control. Only 37% considered screening for lower extremity peripheral artery disease among their T2DM patients and 35% among those with cardiovascular disease.
Physicians mostly follow the ESC/EASD 2013 guidelines, but when it comes to screening for additional conditions including coronary artery disease or peripheral artery disease, or intensifying the antithrombotic regimen there is need for better guidance.
本调查旨在评估欧洲 2 型糖尿病(T2DM)患者的冠状动脉疾病和外周动脉疾病的当前管理和筛查情况,以 2013 年 ESC/EASD(欧洲心脏病学会/欧洲糖尿病研究协会)指南作为基准。
PADDIA/CADDIA 调查是一项针对奥地利、比利时、法国、德国、意大利、荷兰和英国的心脏病专家、血管科医生、糖尿病专家和全科医生的欧洲医学研究合作。
共有 63 名医生完成了问卷,其中 75%的医生表示主要不使用风险评分来评估 T2DM 患者的心血管风险(59%)。超过 90%的专家会检查 T2DM 患者的糖化血红蛋白、血压和低密度脂蛋白胆固醇目标,无论患者是否患有冠状动脉或外周动脉疾病。对于 94%的医生来说,T2DM 的存在会影响患者的管理,方法是优化血糖、血压和低密度脂蛋白胆固醇的控制。只有 37%的医生会考虑对 T2DM 患者进行下肢外周动脉疾病筛查,而 35%的医生会对患有心血管疾病的患者进行筛查。
医生大多遵循 ESC/EASD 2013 指南,但在筛查其他疾病(包括冠状动脉疾病或外周动脉疾病)或强化抗血栓治疗方案方面,需要更好的指导。